View video and audio content from 4D pharma plc.
Our approach (Mandarin)
Manufacturing process overview
KOL Event: MRx0518 SITC 2020 data, 11 November 2020
On Wednesday 11 November 13:00 GMT (08:00 ET), 4D pharma CEO Duncan Peyton and CSO Alex Stevenson are joined by Dr Mark P Lythgoe, Academic Clinical Fellow in Medical Oncology and Pharmacist at Imperial College London, and Dr Shubham Pant, Associate Professor Department of Investigational Cancer Therapeutics and Department of Gastrointestinal Medical Oncology at the University of Texas MD Anderson Cancer Center, to discuss immuno-oncology LBP MRx0518 monotherapy and checkpoint inhibitor combination data published at SITC 2020.
R&D Webinar: Blautix® BHT-II-002 IBS Phase II, 7 October 2020
CSO Dr. Alex Stevenson discusses the results of the BHT-II-002 Phase II trial of Live Biotherapeutic Blautix for the treatment of both IBS-C and IBS-D. He is joined by CEO Duncan Peyton, and CBO Glenn Dourado. Followed by analyst Q&A session.
Webinar: MicroRx® platform, 1 September 2020
4D pharma's Research Director Dr Imke Mulder hosts a webinar discussing 4D's world-leading Live Biotherapeutic discovery platform MicroRx®. Imke is joined by Alex Stevenson, CSO, and senior members of the Research team. The presentation is followed by a Q&A session with analysts
Webinar: Oncology & COVID-19, 5 June 2020
4D's Chairman, CEO and CSO host a virtual R&D event providing an update on the Company's clinical programmes in oncology and COVID-19, including a Q&A with covering analysts